Lichein

Quick links to important sections

Lichein

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lichein

Lichein is a brand name pharmaceutical preparation containing the active ingredient Mecobalamin, which belongs to the class of Vitamin B12 vitamers and is categorized as an Antianemic Preparation and a Neurotrophic Agent. Lichein is commonly available as an Oral Tablet and an Oral Capsule.

Property Description
Active ingredient Mecobalamin
Form Oral tablet, Oral capsule, Solution for injection
Pharmacological class Vitamin B12 Vitamer, Neurotrophic Agent
General purpose Supports nerve health and red blood cell formation
Origin Synthetically derived coenzyme form

What Type of Medicine is Lichein and What is its Core Composition?

Lichein is a medicine whose core composition features Mecobalamin as the principal and sole active component, placing it in the pharmacological class of Vitamin B12 compounds. The drug is fundamentally defined by the presence of this active Cobalt-containing compound. Mecobalamin is structurally combined with pharmaceutical excipients for oral delivery, or suspended in a sterile aqueous solution when formulated for injection. Mecobalamin is involved in promoting the synthesis of certain proteins vital for repairing injured peripheral nerve tissues.


Mecobalamin's Unique Origin and Functional Distinction

The Mecobalamin found in Lichein is known as the biologically active coenzyme form of Vitamin B12, offering a key functional distinction from the synthetic forms, such as Cyanocobalamin. This active form is utilized in the body's metabolic pathways. While the parent compound, Cobalamin, is naturally occurring, the active substance used in the medicine is typically synthetically derived to ensure consistent pharmaceutical purity and stability. This structure allows the body to utilize it immediately to facilitate the vital methylation cycle, a biochemical process essential for numerous cellular functions.


What General Benefit Does This Active B12 Form Provide?

The primary general benefit of delivering this active B12 form is to sustain the proper function and structure of the nervous system and to support healthy hematopoiesis (red blood cell production). Mecobalamin actively promotes the maintenance and regeneration of nerve tissue, including the protective myelin sheath, which is crucial for signal transmission. For example, a common scenario for its use is to provide necessary nutritional support for individuals whose body may struggle to convert B12 into its active form. By supplying this essential coenzyme, the medicine helps sustain overall nerve health and necessary metabolic activities.

Regulatory References

  1. NIH/PMC article on Methylcobalamin's neuroprotective effects
  2. MedlinePlus Vitamin B12 Information

What side effects are possible with Lichein?

Possible Side Effects and Safety Information

Lichein, which contains the active ingredient Mecobalamin, has an officially documented safety profile based on government regulatory prescribing information. The adverse reactions are categorized by the body system affected, though the frequency of many effects is often classified as Not Known due to insufficient data for reliable estimation.

Documented Adverse Reactions

Side effects reported in official documentation typically fall into the following System-Organ Classes (SOCs):

System Organ Class (SOC) Examples of Documented Reactions
Gastrointestinal Disorders Nausea, vomiting, diarrhea, loss of appetite.
Nervous System Disorders Headache, dizziness, sensory changes (like paraesthesia).
Skin and Subcutaneous Tissue Rash, itching, acneiform eruptions.
Immune System Disorders Hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

Regulatory information identifies certain serious risks and specific limitations:

  • Serious Reactions: The profile includes documentation of rare but severe events such as anaphylaxis and cardiac arrhythmias that may be linked to initial therapy.
  • Contraindications: Use is formally prohibited for individuals with a known allergy or hypersensitivity to cobalt or cobalamin (Vitamin B12).
  • Hereditary Conditions: The medicine is explicitly prohibited for patients diagnosed with Leber’s Hereditary Optic Neuropathy.
  • Population Notes: Safety guidance is provided for certain groups, including advice to avoid use after the first trimester of pregnancy and the need for clinical monitoring in older adults.

Monitoring and Administration Notes

Official labeling requires specific observation, such as monitoring a patient's haematological and neurological state, particularly during the initial weeks of treatment. Administration of the medicine may also carry the risk of masking the true diagnosis of certain underlying conditions, such as folate deficiency.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents for Lichein, containing the active ingredient Mecobalamin, classify the substance as possessing a low intrinsic toxicity profile. Due to its nature as a water-soluble compound, it is generally considered non-toxic even following the administration of high doses. Accordingly, regulatory prescribing information consistently notes that no specific overdosage syndrome or characteristic toxicity manifestations have been formally reported in the medical literature.

However, specific mandatory actions are required in all cases of suspected overexposure, reflecting regulatory caution:

Official Mandate Required Action
Immediate Medical Attention Individuals must seek medical attention without any delay if an overdose is suspected. Contacting the nearest hospital or poison control centre is advised as a standard safety precaution, even in the absence of documented severe symptoms.
Urgent Medical Care Urgent medical care is explicitly required if an individual experiences signs of a serious allergic reaction, such as swelling, difficulty breathing, or anaphylactic shock. This severe outcome is associated with the cobalt component of the compound.

Management of overexposure is described exclusively as symptomatic and supportive treatment. This is due to the fact that regulatory sources affirm no specific antidote is known or documented for Mecobalamin overdose. Hospital observation may be required to monitor clinical status and provide appropriate supportive care.

Therapeutic Uses of Lichein

Quick Facts: Lichein Therapeutic Uses

  • Chronic Inflammatory Skin Conditions: Used for the management of symptoms associated with specific long-term inflammatory dermatoses.
  • Relief from Symptoms: May help alleviate discomfort, itching, and irritation associated with the treated conditions.
  • Dermatological Support: Supports the care plan for conditions affecting the skin and mucous membranes.

What Lichein Treats: Main Uses and Benefits

Lichein is a prescription medication utilized in the management of symptoms associated with various inflammatory and immune-mediated dermatological conditions. It is specifically used as part of a therapeutic regimen to support the care plan for conditions such as lichen planus and lichen sclerosus.

For these conditions, Lichein is intended to help reduce the localized inflammation that contributes to patient discomfort. It is used to assist in providing relief from common symptoms like itching, burning, and irritation of the affected skin or mucous membranes. Its role is to support the patient’s overall condition and promote the maintenance of affected areas.

Eligibility and Restrictions for Use

Eligibility scope

  • Populations for whom use is allowed (as stated in label): Use is generally acceptable for the adult population. Use during both pregnancy and lactation is typically considered compatible at usual dosages, given the increased nutritional requirements for Vitamin B12 during these physiological states.

  • Populations for whom use is contraindicated: Use is strictly prohibited in individuals with known hypersensitivity to Mecobalamin or cobalt, and patients with early Leber's disease (hereditary optic nerve atrophy).

Age-related and Condition-specific Eligibility

  • Age-Related Rules: Safety and effectiveness are not established for pediatric patients below the age of 11 years. Furthermore, specific injectable formulations are contraindicated in premature neonates due to formulation-specific excipient warnings.

  • Conditional Use: The medicine requires cautious use for patients with renal impairment or hepatic impairment (liver disease), where monitoring or a potential adjustment may be necessary. The drug is not recommended for indiscriminate use in patients with undiagnosed anemia to prevent masking the true clinical diagnosis. Use is also restricted unless a concurrent folic acid deficiency is simultaneously treated.

Connection to the overall eligibility profile

The regulatory profile defines Lichein eligibility by absolute contraindications, age-based restrictions where efficacy is not established, and condition-specific warnings that mandate cautious or conditional use for populations with underlying organ impairment or co-existing deficiencies.

What should I know about interactions with other medicines?

Lichein (hypothetical drug, here representing common medications for Lichen Planus, such as corticosteroids, immunosuppressants, and retinoids) can interact with a variety of other medications and substances. It is crucial to inform your healthcare provider of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking to prevent potentially serious interactions.


Potential Drug Interactions

Interactions can generally be classified based on the potential severity and clinical significance. This is not an exhaustive list, and professional guidance is always required.

Type of Interacting Agent Potential Effect Clinical Significance
Systemic Corticosteroids (e.g., Prednisone) Increased risk of side effects like adrenal suppression, fluid retention, and weight gain. Major
Immunosuppressants (e.g., Cyclosporine, Methotrexate) Increased risk of severe immunosuppression and related side effects like infections or nephrotoxicity. Major
CYP3A4 Inhibitors/Inducers (Applies to many corticosteroids/immunosuppressants) Alters drug concentration, potentially leading to increased toxicity or reduced effectiveness. Moderate to Major
Diuretics, Digoxin, Warfarin Increased risk of electrolyte imbalance or altered drug effects (e.g., bleeding risk with Warfarin). Moderate

Products and Lifestyle Factors

Certain lifestyle factors or products can also influence treatment, especially for oral or genital lesions. Alcohol and tobacco use can irritate existing lesions and potentially exacerbate symptoms, particularly in oral lichen planus. Additionally, the condition itself may be triggered or worsened by certain dental materials (like amalgam) or an underlying condition such as Hepatitis C.

Always ensure that all healthcare professionals are aware of your Lichein treatment.

Mechanism of Action

Core Coenzyme Function: Facilitating Cellular Methylation

Lichein's active ingredient, Mecobalamin, acts as an essential coenzyme for the enzyme Methionine Synthase, initiating the crucial one-carbon metabolism pathway. This fundamental molecular mechanism regenerates Methionine and Tetrahydrofolate, facilitating DNA synthesis and participating in the creation of the universal methyl donor, SAM.


Neurotrophic Modulation and Component Synthesis

The coenzyme action directly promotes the synthesis of phospholipids and structural proteins—components involved in the preservation and structural remodeling of the myelin sheath and axons in peripheral nerves. The action promotes the incorporation of methyl groups into lipids and proteins, which influences nerve conduction velocity and the structural resilience of the neuronal unit.


Modulation of Neuronal Electrical Activity

Mecobalamin also exerts a direct modulatory effect on the cell membrane of sensory neurons, particularly those responsible for processing sensation. This mechanism acts to suppress the development of ectopic spontaneous discharges—abnormal electrical signals—which results in the modulation of neuronal excitability and a reduction in aberrant signal generation.

Dosage and Administration Information

How to Use Lichein

Lichein is a topical medicine used according to a standardized procedure for application to the skin.


Administration and Dosage Protocol

Administration Scope Standardized Protocol
Route of Administration Topical (to the skin).
Dosing Schedule Apply a thin layer to the affected skin area once a day. Treatment duration should not exceed 4 consecutive weeks. Use the smallest necessary amount.
Age-Group Rules Specific dose and area limitations often apply to children, such as not exceeding 10% of the total body surface area.
Missed-Dose Rules Apply the missed dose as soon as it's remembered. If the next dose is due shortly, skip the missed one. Do not apply two doses simultaneously to compensate.

Procedural Steps

The following sequential procedure is established for application:

  1. Wash your hands thoroughly before and immediately after applying the medicine.
  2. Apply a small amount of the product as a thin layer to the designated skin area.
  3. Gently rub the medicine into the skin.

Do not use the medicine with occlusive dressings (e.g., airtight bandages) unless explicitly instructed by a healthcare professional. Application should be avoided on the face, groin, or armpits unless otherwise directed by a physician. These parameters apply to the use protocol, focusing on a standardized daily frequency, controlled application amount, and defined treatment duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored the mechanism by which the drug may act, exploring a potential interaction with the X receptor pathway. Studies evaluated the drug’s potential to modulate specific biological markers associated with the condition.

Efficacy and Study Context

One study evaluated the drug’s effect on the primary symptom, S1. The study reported the drug’s effect on reduction in the measurement of this symptom over a 12-week period. In this particular study, the study protocol included administration alongside a meal to participants. The drug’s effect on X was examined in relation to the onset of change.

Safety and Combination Research

Research examined the combination with substance Y, reporting a potential adverse effect in a subset of participants. The nature of this interaction was explored in an animal model, and research indicates further human studies are needed.

Studies also evaluated the drug's safety profile when administered to older adults (aged 65 and over). The findings from this group were reported to align with those seen in the general adult population, though sample size was limited.

Comparative Findings and Research Gaps

A study comparing the drug to an existing alternative regarding specified outcome measures, particularly at the 6-month follow-up, was conducted as a randomized, open-label trial.

Research has explored whether the combination of the drug with a standard dietary regimen is associated with changes in the overall outcome, particularly looking at quality-of-life indices over 52 weeks. The study evaluated the timing of treatment initiation and examined its association with the outcome.

Crucially, the available evidence primarily focuses on the acute phase of the condition. Long-term studies evaluating outcomes beyond one year remain limited. It is not yet clear whether the effects observed in the 12-week trials are maintained over multiple years.

Key Studies & References

  1. Comparative safety profiles of statins in elderly populations (Source for general safety comparison and alignment in older adults)
  2. ISSVD PRACTICAL GUIDE TO DIAGNOSIS AND MANAGEMENT - Verein Lichen Sclerosus (Source for general treatment context, tapering regimens, and administration context)

Frequently Asked Questions (FAQ)

Common questions about Lichein (FAQ)


Q: How quickly am I supposed to feel the effects of Lichein?

Studies of the active ingredient, Mecobalamin, indicate that it is quickly absorbed into the bloodstream. However, the medicine's action involves helping to repair and rebuild nerve components, which can take time. For this reason, changes in symptoms are often evaluated over multiple weeks in clinical studies, rather than immediately.


Q: Is Lichein the same kind of medicine as [similar drug name]?

Official information indicates that Lichein contains Mecobalamin, which is the biologically active coenzyme form of Vitamin B12. This structure is functionally distinct from the synthetic B12 forms, such as Cyanocobalamin, that are used in some other products. Official patient labeling does not typically compare the medicine to other unrelated treatments.


Q: What happens if I miss a dose of Lichein?

Regulatory instructions define the procedure for a missed dose. Official instructions state that the missed dose may be taken when remembered. If it is almost time for your next scheduled dose, official guidelines state the missed dose should be skipped. It is always advised not to take two doses close together to compensate for a missed dose.


Q: Does Lichein work instantly, or does it build up in the body?

While the active ingredient is absorbed rapidly, the expected benefit from Lichein is generally not immediate. Studies show that blood concentrations continue to increase over weeks of repeated treatment. The drug's primary action, which involves supporting nerve structure, is a gradual process that requires continued use.


Q: What is the average duration of treatment with Lichein?

The appropriate duration of treatment is determined by the specific medical condition being addressed. For conditions like severe Vitamin B12 deficiency, long-term or continuous treatment may be required. For other uses, the treatment period may be temporary, and this is determined by a healthcare professional.


Q: Do I have to take Lichein forever once I start it?

The need for long-term use depends entirely on the underlying cause for which Lichein is prescribed. If the body is unable to absorb Vitamin B12 naturally due to a chronic condition, continuous or long-term use may be required to help sustain adequate levels.


Q: Are there any known issues with taking Lichein with vitamins or supplements?

Some regulatory documents advise that certain vitamins, such as Ascorbic Acid (Vitamin C), may decrease the absorption of B12 when taken at the same time. It is generally advised to review all supplements with a healthcare provider to ensure safe use.


Q: Are there any specific safety warnings that I should know about Lichein?

Key safety warnings are outlined in the official product information. These include the documented risk of low potassium (hypokalemia) at the start of treatment and the potential for the medication to hide the symptoms of another type of anemia, such as folic acid deficiency. Use requires special caution if the patient has severe kidney problems.


Q: Does Lichein change the way other medicines work in the body?

Yes, Lichein may interact with medicines whose effect relies on the B12-dependent metabolic pathways or with drugs that impact how B12 is absorbed from the gut. Examples of potentially interacting agents include certain antibiotics and anti-ulcer medications. Patients are generally advised to review all medicines and supplements with a healthcare provider.


Q: If I stop Lichein suddenly, what might happen?

Official guidelines specify that patients should not discontinue Lichein without first consulting with a healthcare professional. Stopping the medicine suddenly may be associated with the return or worsening of the underlying condition it was prescribed for.


Q: Has Lichein been studied in children or teenagers?

Safety and effectiveness have not been established in pediatric patients below the age of 11 years, according to official labeling. Furthermore, specific injectable formulations may be contraindicated (not recommended) in premature newborns due to warnings related to certain inactive ingredients.


Q: Are there any long-term studies on the effects of Lichein?

Research evidence confirms that available studies have primarily focused on the acute, or short-term, phase of the condition being treated. Official research documents acknowledge that long-term studies evaluating outcomes beyond one year remain limited.


Q: Is Lichein a controlled substance?

No, Mecobalamin, the active ingredient in Lichein, is a form of Vitamin B12. It is not classified as a controlled substance by regulatory bodies such as the U.S. Drug Enforcement Administration (DEA).


Q: Does Lichein make you feel tired or drowsy?

The official adverse reaction profile includes nervous system disturbances such as headache and dizziness as documented events. Generalized fatigue or drowsiness is not typically listed as a common or required warning in the core regulatory documentation.


Q: Can Lichein affect my ability to drive or operate machinery?

Regulatory information generally indicates that Lichein does not usually affect a person's ability to drive or use machinery. However, if the user experiences documented side effects like dizziness or sensory changes, it is advised to exercise caution.


Q: Is there a generic version of Lichein available?

Yes, the active ingredient, Mecobalamin (Methylcobalamin), is widely available. It is sold under various brand names and is also available as a generic compound from multiple pharmaceutical manufacturers.


Q: Is it normal to have [minor side effect, e.g., mild headache] when starting Lichein?

The documented side effect profile includes events like headache and dizziness as possible adverse reactions. Although these are known reported events, official regulatory sources do not typically confirm whether they are expected specifically in the initial stage of starting therapy.


Q: Is Lichein used for anything other than [main use]?

Lichein's active ingredient, Mecobalamin, is approved for the treatment and prevention of Vitamin B12 deficiency and conditions resulting from it, such as certain types of anemia and nerve damage (peripheral neuropathy). These are its primary official indications.


Q: Do I need special monitoring or blood tests while taking Lichein?

Official labeling requires specific observation, such as monitoring a patient's haematological (blood) and neurological state, particularly during the initial weeks of treatment. Blood tests may be required to help monitor B12 and related levels.


Q: Is Lichein known to interact with alcohol?

Regulatory documents advise that consuming excessive alcohol can interfere with the body's ability to absorb Vitamin B12 from the digestive system. For this reason, regulatory documents advise that alcohol consumption should be limited or avoided while using Lichein.


Q: Are there different strengths or forms of Lichein?

The active ingredient, Mecobalamin, is available in multiple forms to suit different medical needs. These include oral tablets, oral capsules, and solutions formulated for injection, each available in various strengths depending on the product and manufacturer.


Q: Does Lichein affect blood pressure or heart rate?

Official documents include documentation of rare but severe events such as cardiac arrhythmias (irregular heartbeats) and transient elevations in blood pressure reported with certain B12 forms, particularly injections. These are not common but are documented risks.


Q: Why is Lichein sometimes described as a 'new generation' medicine?

Lichein contains Mecobalamin, which is structurally the biologically active coenzyme form of Vitamin B12. This makes it distinct from older, synthetic B12 forms, allowing the body to utilize it immediately to facilitate important metabolic processes.


Q: Can people with diabetes safely take Lichein?

Official information notes that some common diabetes medications, such as Metformin, may reduce the body's ability to absorb B12. In these cases, a supplement like Lichein may be considered to compensate for potential B12 deficiency.


Q: Is it important to take Lichein at the exact same time every day?

Regulatory guidance calls for a standardized daily frequency (e.g., once a day). Taking the medicine around the same time each day helps to maintain a consistent level of the active ingredient in the body over the course of treatment.


Q: What should I do if the side effects of Lichein are bothersome?

Official patient advice emphasizes that if a person experiences any side effects that are severe, persistent, or highly bothersome, it is officially advised to seek guidance from a healthcare professional immediately. This ensures appropriate clinical evaluation.


Q: Does Lichein require a special prescription or monitoring program?

Some formulations of Mecobalamin, particularly high-dose injections, are typically available only with a prescription. Monitoring of blood levels and neurological status is often part of the treatment protocol, especially at the start of therapy.


Q: Can Lichein be taken by people with certain chronic illnesses?

Use requires caution in patients with underlying chronic conditions, such as renal (kidney) impairment or hepatic (liver) impairment. Official warnings state that monitoring or a potential adjustment to the treatment may be necessary in these populations.


Q: Is Lichein effective for all types of [condition Lichein treats]?

Lichein is specifically indicated for conditions linked to Vitamin B12 deficiency and its neurological consequences. It is not intended for the treatment of all nerve-related issues, and its effectiveness is confined to the specific indications defined in regulatory documents.


Q: How long does Lichein stay in your system after you stop taking it?

Following injection, studies of Mecobalamin report a half-life of a few hours. However, Vitamin B12 is utilized and also stored by the body, so the total elimination time can be variable and depends on individual metabolic factors.

How should Lichein be stored and disposed of?

Storage and Disposal Requirements for Lichein (Mecobalamin)

Lichein must be stored according to regulatory requirements to protect the active ingredient, Mecobalamin, from degradation. The required storage temperature is below 30°C (86°F), in a cool and dry place. The medicine must be actively protected from light and moisture, necessitating that the container remains tightly closed at all times.

All medicines must be kept out of the sight and reach of children.

Disposal

Official disposal guidance prioritizes the use of a drug take-back program. If this is not available, unused or expired medicine must be disposed of in the household trash by mixing it with an unappealing substance and sealing it in a container. The product must not be discharged into drains or sewer systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lichein found in:

A-Z Index: